suramin has been researched along with 2019 Novel Coronavirus Disease in 9 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin was originally used as an antiparasitic drug in clinics." | 1.91 | Suramin Disturbs the Association of the N-Terminal Domain of SARS-CoV-2 Nucleocapsid Protein with RNA. ( Guo, C; Li, X; Lin, D; Xu, H; Yu, J, 2023) |
| "Suramin was initially developed as a successful antiparasitic drug but has also shown promising antiviral and antibacterial activities." | 1.62 | Targeted Redesign of Suramin Analogs for Novel Antimicrobial Lead Development. ( Conn, GL; Dey, D; Ramakumar, S, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 9 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dey, D | 1 |
| Ramakumar, S | 1 |
| Conn, GL | 1 |
| Mravinec, M | 1 |
| Bajc, G | 1 |
| Butala, M | 1 |
| Dey, SK | 1 |
| Saini, M | 1 |
| Dhembla, C | 1 |
| Bhatt, S | 1 |
| Rajesh, AS | 1 |
| Anand, V | 1 |
| Das, HK | 1 |
| Kundu, S | 1 |
| Guo, C | 1 |
| Xu, H | 1 |
| Li, X | 1 |
| Yu, J | 1 |
| Lin, D | 1 |
| Metwally, K | 2 |
| Abo-Dya, NE | 2 |
| Alahmdi, MI | 1 |
| Albalawi, MZ | 1 |
| Yahya, G | 1 |
| Aljoundi, A | 2 |
| Salifu, EY | 1 |
| Elamin, G | 1 |
| Ibrahim, MAA | 1 |
| Sayed, Y | 1 |
| Fanucchi, S | 1 |
| Soliman, MES | 2 |
| Kwon, PS | 1 |
| Xu, S | 1 |
| Oh, H | 1 |
| Kwon, SJ | 1 |
| Rodrigues, AL | 1 |
| Feroz, M | 1 |
| Fraser, K | 1 |
| He, P | 1 |
| Zhang, F | 1 |
| Hong, JJ | 1 |
| Linhardt, RJ | 1 |
| Dordick, JS | 1 |
| Hamdan, AME | 1 |
| Alrashidi, MN | 1 |
| Alturki, MS | 1 |
| Aly, OM | 1 |
| Ibrahim, M | 1 |
| Salgado-Benvindo, C | 1 |
| Thaler, M | 1 |
| Tas, A | 1 |
| Ogando, NS | 1 |
| Bredenbeek, PJ | 1 |
| Ninaber, DK | 1 |
| Wang, Y | 1 |
| Hiemstra, PS | 1 |
| Snijder, EJ | 1 |
| van Hemert, MJ | 1 |
| Ao, Z | 1 |
| Chan, M | 1 |
| Ouyang, MJ | 1 |
| Olukitibi, TA | 1 |
| Mahmoudi, M | 1 |
| Kobasa, D | 1 |
| Yao, X | 1 |
9 other studies available for suramin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Targeted Redesign of Suramin Analogs for Novel Antimicrobial Lead Development.
Topics: Anti-Bacterial Agents; Antiviral Agents; COVID-19; Humans; RNA, Viral; SARS-CoV-2; Suramin | 2021 |
Surface plasmon resonance approach to study drug interactions with SARS-CoV-2 RNA-dependent RNA polymerase highlights treatment potential of suramin.
Topics: Antiviral Agents; COVID-19; Drug Interactions; Humans; RNA-Dependent RNA Polymerase; RNA, Viral; SAR | 2021 |
Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2.
Topics: Anidulafungin; Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; SARS-CoV-2; Suramin | 2022 |
Suramin Disturbs the Association of the N-Terminal Domain of SARS-CoV-2 Nucleocapsid Protein with RNA.
Topics: COVID-19; Humans; Models, Molecular; Molecular Docking Simulation; Nucleocapsid Proteins; RNA, Viral | 2023 |
The Unusual Architecture of RNA-Dependent RNA Polymerase (RdRp)'s Catalytic Chamber Provides a Potential Strategy for Combination Therapy against COVID-19.
Topics: Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; RNA-Dependent RNA Polymerase; RNA, | 2023 |
Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions.
Topics: Angiotensin-Converting Enzyme 2; COVID-19; Heparitin Sulfate; Humans; SARS-CoV-2; Spike Glycoprotein | 2023 |
Investigation of Simultaneous and Sequential Cooperative Homotropic Inhibitor Binding to the Catalytic Chamber of SARS-CoV-2 RNA-dependent RNA Polymerase (RdRp).
Topics: Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; RNA-Dependent RNA Polymerase; RNA, | 2023 |
Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; | 2020 |
Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry.
Topics: Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Cell Line; Chlorocebus aethiops; | 2021 |